The metabolism of Ropinirole can be decreased when combined with Atazanavir. The metabolism of Letermovir can be decreased when combined with Ropinirole. Haloperidol may increase the sedative activities of Ropinirole. Olanzapine may increase the sedative activities of Ropinirole. Oxprenolol may increase the sedative activities of Ropinirole. The risk or severity of adverse effects can be increased when Ropinirole is combined with Lisinopril. Estazolam may increase the sedative activities of Ropinirole. Ropinirole may increase the hypertensive activities of Droxidopa. The metabolism of Amprenavir can be decreased when combined with Ropinirole. Doxylamine may increase the sedative activities of Ropinirole. The metabolism of Ropinirole can be decreased when combined with Azithromycin. Clemastine may increase the sedative activities of Ropinirole. The metabolism of Clopidogrel can be decreased when combined with Ropinirole. The metabolism of Ritonavir can be decreased when combined with Ropinirole. The metabolism of Sparteine can be decreased when combined with Ropinirole. The serum concentration of Ropinirole can be increased when it is combined with Chlorotrianisene. The therapeutic efficacy of Tramadol can be decreased when used in combination with Ropinirole. Maprotiline may increase the sedative activities of Ropinirole. Molindone may increase the sedative activities of Ropinirole. The metabolism of Pentamidine can be decreased when combined with Ropinirole. Ropinirole may increase the atrioventricular blocking (AV block) activities of Acebutolol. Ecopipam may increase the sedative activities of Ropinirole. The metabolism of Ropinirole can be decreased when combined with Bortezomib. The metabolism of Nicardipine can be decreased when combined with Ropinirole. Halothane may increase the sedative activities of Ropinirole. Levocetirizine may increase the sedative activities of Ropinirole. Ropinirole may increase the atrioventricular blocking (AV block) activities of Arotinolol. clomethiazole may increase the sedative activities of Ropinirole. The risk or severity of adverse effects can be increased when Ropinirole is combined with Perindopril. Opium may increase the sedative activities of Ropinirole. The metabolism of Ropinirole can be decreased when combined with Sildenafil. The risk or severity of adverse effects can be increased when Imidapril is combined with Ropinirole. Zolpidem may increase the sedative activities of Ropinirole. The metabolism of Lorcaserin can be decreased when combined with Ropinirole. The metabolism of Ropinirole can be decreased when combined with Venlafaxine. The metabolism of Dasabuvir can be decreased when combined with Ropinirole. The metabolism of Warfarin can be decreased when combined with Ropinirole. The metabolism of Voxilaprevir can be decreased when combined with Ropinirole. The metabolism of Ropinirole can be decreased when combined with Posaconazole. The metabolism of Ropinirole can be decreased when combined with Dronedarone. Promethazine may increase the sedative activities of Ropinirole. The serum concentration of Ropinirole can be increased when it is combined with Palbociclib. Levetiracetam may increase the sedative activities of Ropinirole. The metabolism of Dolasetron can be decreased when combined with Ropinirole. The metabolism of Nabumetone can be decreased when combined with Ropinirole. The risk or severity of adverse effects can be increased when Lofexidine is combined with Ropinirole. The risk or severity of adverse effects can be increased when Clofarabine is combined with Ropinirole. The serum concentration of Ropinirole can be increased when it is combined with Synthetic Conjugated Estrogens, B. The metabolism of Ropinirole can be decreased when combined with Indinavir. Quazepam may increase the sedative activities of Ropinirole. Lorazepam may increase the sedative activities of Ropinirole. The metabolism of Nitric Oxide can be decreased when combined with Ropinirole. Amineptine may decrease the antihypertensive activities of Ropinirole. The metabolism of Proguanil can be decreased when combined with Ropinirole. The risk or severity of adverse effects can be increased when Ropinirole is combined with Dipyridamole. The metabolism of Umeclidinium can be decreased when combined with Ropinirole. The metabolism of Ropinirole can be increased when combined with Lumacaftor. Clobazam may increase the sedative activities of Ropinirole. The risk or severity of adverse effects can be increased when Ropinirole is combined with Methyclothiazide. Pipotiazine may increase the sedative activities of Ropinirole. Triflupromazine may increase the sedative activities of Ropinirole. Thioridazine may increase the sedative activities of Ropinirole. The therapeutic efficacy of Ropinirole can be decreased when used in combination with Metoclopramide. The serum concentration of Ropinirole can be increased when it is combined with Estriol. Ropinirole may increase the atrioventricular blocking (AV block) activities of Alprenolol. The metabolism of Dextroamphetamine can be decreased when combined with Ropinirole. The therapeutic efficacy of Ropinirole can be decreased when used in combination with Sarilumab. Fospropofol may increase the sedative activities of Ropinirole. The metabolism of Valbenazine can be decreased when combined with Ropinirole. The risk or severity of adverse effects can be increased when Ropinirole is combined with Telmisartan. Perampanel may increase the sedative activities of Ropinirole. The metabolism of Dinoprostone can be decreased when combined with Ropinirole. The metabolism of Ropinirole can be decreased when combined with Mexiletine. Ethanol may increase the sedative activities of Ropinirole. Thiothixene may increase the sedative activities of Ropinirole. The metabolism of Darifenacin can be decreased when combined with Ropinirole. Meprobamate may increase the sedative activities of Ropinirole. Trichloroethylene may increase the sedative activities of Ropinirole. Mesoridazine may increase the sedative activities of Ropinirole. The risk or severity of adverse effects can be increased when Ropinirole is combined with Amiloride. The metabolism of Ropinirole can be decreased when combined with Fluconazole. The serum concentration of Ropinirole can be decreased when it is combined with Enzalutamide. The serum concentration of Eliglustat can be increased when it is combined with Ropinirole. Loratadine may increase the sedative activities of Ropinirole. Bromperidol may increase the sedative activities of Ropinirole. The metabolism of Nifedipine can be decreased when combined with Ropinirole. Clorazepate may increase the sedative activities of Ropinirole. The metabolism of Ropinirole can be decreased when combined with Phenoxypropazine. The metabolism of Mephenytoin can be decreased when combined with Ropinirole. The metabolism of Oxtriphylline can be decreased when combined with Ropinirole. Melatonin may increase the sedative activities of Ropinirole. Alprazolam may increase the sedative activities of Ropinirole. DPDPE may increase the sedative activities of Ropinirole. The serum concentration of Ropinirole can be decreased when it is combined with Tocilizumab. The metabolism of Dacarbazine can be decreased when combined with Ropinirole. The metabolism of Idarubicin can be decreased when combined with Ropinirole. The metabolism of Procainamide can be decreased when combined with Ropinirole. Metaxalone may increase the sedative activities of Ropinirole. The metabolism of Astemizole can be decreased when combined with Ropinirole. Brexpiprazole may increase the sedative activities of Ropinirole. Sufentanil may increase the sedative activities of Ropinirole. The risk or severity of adverse effects can be increased when Ropinirole is combined with Isosorbide Dinitrate. The risk or severity of adverse effects can be increased when Pramipexole is combined with Ropinirole. The metabolism of Erlotinib can be decreased when combined with Ropinirole. The risk or severity of adverse effects can be increased when Ropinirole is combined with Bupropion. The metabolism of Albendazole can be decreased when combined with Ropinirole. The therapeutic efficacy of Ropinirole can be decreased when used in combination with Lumateperone. Ethyl carbamate may increase the sedative activities of Ropinirole. The metabolism of Vinblastine can be decreased when combined with Ropinirole. The metabolism of Ropinirole can be decreased when combined with Telithromycin. The metabolism of Ropinirole can be decreased when combined with Crizotinib. Fexofenadine may increase the sedative activities of Ropinirole. Desipramine may increase the sedative activities of Ropinirole. Methadone may increase the sedative activities of Ropinirole. Felbamate may increase the sedative activities of Ropinirole. The serum concentration of the active metabolites of Tamoxifen can be reduced when Tamoxifen is used in combination with Ropinirole resulting in a loss in efficacy. Ropinirole may increase the atrioventricular blocking (AV block) activities of Penbutolol. Butabarbital may increase the sedative activities of Ropinirole. Dexbrompheniramine may increase the sedative activities of Ropinirole. The risk or severity of adverse effects can be increased when Ropinirole is combined with Isosorbide Mononitrate. The risk or severity of adverse effects can be increased when Obinutuzumab is combined with Ropinirole. Methapyrilene may increase the sedative activities of Ropinirole. The risk or severity of adverse effects can be increased when Arsenic trioxide is combined with Ropinirole. Tapentadol may increase the sedative activities of Ropinirole. Remifentanil may increase the sedative activities of Ropinirole. Ergonovine may increase the vasoconstricting activities of Ropinirole. The serum concentration of Ropinirole can be increased when it is combined with Equol. The risk or severity of adverse effects can be increased when Ropinirole is combined with Enalapril. The metabolism of Cevimeline can be decreased when combined with Ropinirole. The risk or severity of adverse effects can be increased when Ropinirole is combined with Indapamide.